======= FLI1 ======= == Gene Information == * **Official Symbol**: FLI1 * **Official Name**: Fli-1 proto-oncogene, ETS transcription factor * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=2313|2313]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q01543|Q01543]] * **Interactions**: [[https://thebiogrid.org/search.php?search=FLI1&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20FLI1|Open PubMed]] * **OMIM**: [[https://omim.org/entry/193067|Open OMIM]] == Function Summary == * **Entrez Summary**: This gene encodes a transcription factor containing an ETS DNA-binding domain. The gene can undergo a t(11;22)(q24;q12) translocation with the Ewing sarcoma gene on chromosome 22, which results in a fusion gene that is present in the majority of Ewing sarcoma cases. An acute lymphoblastic leukemia-associated t(4;11)(q21;q23) translocation involving this gene has also been identified. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2012]. * **UniProt Summary**: Sequence-specific transcriptional activator (PubMed:24100448, PubMed:26316623, PubMed:28255014). Recognizes the DNA sequence 5'-C[CA]GGAAGT-3'. {ECO:0000269|PubMed:24100448, ECO:0000269|PubMed:26316623, ECO:0000269|PubMed:28255014}. |Ets| |SAM PNT| |megakaryocyte development| |megakaryocyte differentiation| |bone cell development| |myeloid cell development| |RNA polymerase II distal enhancer sequence-specific DNA binding| |bone development| |myeloid cell differentiation| |nuclear body| |hemostasis| |blood circulation| |chromatin binding| |circulatory system process| |DNA-binding transcription activator activity, RNA polymerase II-specific| |skeletal system development| |regulation of body fluid levels| |RNA polymerase II proximal promoter sequence-specific DNA binding| |hemopoiesis| |hematopoietic or lymphoid organ development| |immune system development| |DNA-binding transcription factor activity| |animal organ morphogenesis| |positive regulation of transcription by RNA polymerase II| |DNA binding| |positive regulation of transcription, DNA-templated| |DNA-binding transcription factor activity, RNA polymerase II-specific| |positive regulation of nucleic acid-templated transcription| |positive regulation of RNA biosynthetic process| |cell development| |positive regulation of RNA metabolic process| |positive regulation of nucleobase-containing compound metabolic process| |positive regulation of macromolecule biosynthetic process| |system process| |positive regulation of cellular biosynthetic process| |positive regulation of gene expression| |positive regulation of biosynthetic process| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|-2.67| |[[:results:exp365|I-BRD9 4μM R07 exp365]]|-2.42| |[[:results:exp429|Rapamycin 0.001μM R08 exp429]]|-2.19| |[[:results:exp308|Rapamycin 2μM plus FK-506 5μM R07 exp308]]|-2.02| |[[:results:exp483|FTY720 3μM R08 exp483]]|-1.95| |[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|-1.93| |[[:results:exp115|A-366 10μM R03 exp115]]|-1.91| |[[:results:exp229|Dimethyloxaloylglycine 100μM R05 exp229]]|-1.91| |[[:results:exp29|Rapamycin 1μM R00 exp29]]|-1.83| |[[:results:exp242|Radicicol 0.16μM R05 exp242]]|-1.82| |[[:results:exp410|THZ531 0.11 to 0.125μM on day4 R07 exp410]]|-1.8| |[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|-1.8| |[[:results:exp306|Rapamycin 2μM R07 exp306]]|-1.78| |[[:results:exp432|YM155 0.001μM R08 exp432]]|-1.77| |[[:results:exp81|Selumetinib 20μM R02 exp81]]|-1.76| |[[:results:exp470|Chloroquine 32μM R08 exp470]]|-1.76| |[[:results:exp220|BAY-598 4μM R05 exp220]]|-1.75| |[[:results:exp83|Trametinib 10μM R02 exp83]]|-1.75| |[[:results:exp347|Cyclosporin-A 0.8μM R07 exp347]]|-1.73| |[[:results:exp277|Curcumin 6.5μM R06 exp277]]|-1.72| |[[:results:exp344|Chlorpromazine 10μM R07 exp344]]|-1.7| |[[:results:exp234|Ethanol 0.01 R05 exp234]]|-1.7| |[[:results:exp317|Geldanamycin 0.015 to 0.05μM on day4 R07 exp317]]|-1.7| |[[:results:exp504|MK2206 4μM R08 exp504]]|-1.7| |[[:results:exp34|Rotenone 20μM R00 exp34]]|1.81| |[[:results:exp226|Cerivastatin 0.15μM R05 exp226]]|1.92| |[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|1.98| |[[:results:exp114|A-196 10μM R03 exp114]]|2.06| |[[:results:exp106|UM131593 0.2μM R03 exp106]]|2.6| ^Gene^Correlation^ |[[:human genes:m:med23|MED23]]|0.548| |[[:human genes:c:ccdc101|CCDC101]]|0.536| |[[:human genes:e:erg|ERG]]|0.526| |[[:human genes:z:znf319|ZNF319]]|0.511| |[[:human genes:h:hars|HARS]]|0.511| |[[:human genes:l:lmo2|LMO2]]|0.493| |[[:human genes:z:zbtb44|ZBTB44]]|0.49| |[[:human genes:x:xpot|XPOT]]|0.488| |[[:human genes:z:zfx|ZFX]]|0.483| |[[:human genes:h:hdac8|HDAC8]]|0.47| |[[:human genes:t:taf5l|TAF5L]]|0.467| |[[:human genes:x:xpo6|XPO6]]|0.467| |[[:human genes:r:rnmt|RNMT]]|0.467| |[[:human genes:m:maml1|MAML1]]|0.463| |[[:human genes:m:mllt1|MLLT1]]|0.46| |[[:human genes:c:cbfb|CBFB]]|0.451| |[[:human genes:m:med16|MED16]]|0.448| |[[:human genes:m:mef2c|MEF2C]]|0.446| |[[:human genes:t:tle4|TLE4]]|0.441| |[[:human genes:d:dnajc3|DNAJC3]]|0.436| |[[:human genes:m:med13|MED13]]|0.434| |[[:human genes:t:tada1|TADA1]]|0.434| |[[:human genes:i:irf2bp2|IRF2BP2]]|0.432| |[[:human genes:t:taf6l|TAF6L]]|0.43| |[[:human genes:t:tmed10|TMED10]]|0.429| |[[:human genes:s:sox7|SOX7]]|0.428| |[[:human genes:d:dpagt1|DPAGT1]]|0.428| |[[:human genes:d:dhx29|DHX29]]|0.427| |[[:human genes:l:ldb1|LDB1]]|0.426| |[[:human genes:s:ssbp2|SSBP2]]|0.426| |[[:human genes:d:ddx5|DDX5]]|0.425| |[[:human genes:u:ube2l3|UBE2L3]]|0.423| |[[:human genes:t:tcf4|TCF4]]|0.423| |[[:human genes:l:lsmd1|LSMD1]]|0.416| |[[:human genes:v:vmp1|VMP1]]|0.41| |[[:human genes:d:dcaf7|DCAF7]]|0.409| |[[:human genes:b:brpf1|BRPF1]]|0.408| |[[:human genes:o:otud5|OTUD5]]|0.407| |[[:human genes:g:gmppb|GMPPB]]|0.406| |[[:human genes:b:btaf1|BTAF1]]|0.406| |[[:human genes:r:rptor|RPTOR]]|0.405| |[[:human genes:h:hmgb2|HMGB2]]|0.404| |[[:human genes:z:znf592|ZNF592]]|0.404| |[[:human genes:t:trmt10a|TRMT10A]]|0.403| |[[:human genes:g:gtf3c2|GTF3C2]]|0.402| |[[:human genes:b:bcl7a|BCL7A]]|0.402| |[[:human genes:m:med13l|MED13L]]|0.401| |[[:human genes:l:ldlrap1|LDLRAP1]]|0.401| |[[:human genes:b:brd9|BRD9]]|0.4| Global Fraction of Cell Lines Where Essential: 4/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|1/28| |bone|3/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 3113 * **Expression level (log2 read counts)**: 6.49 {{:chemogenomics:nalm6 dist.png?nolink |}}